A double-blind, placebo-controlled, randomised trial to prove the ther
A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with multiple sclerosis.
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- ATL1102
What it measured
Main measures
• the cumulative number of new active lesions (either new gadolinium-enhancing, or non-enhancing, new or enlarging on T2) on MRI (to include all lesions from weeks 4, 8, and 12), corrected for the number of enhancing lesions at baseline
MRI lesions
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: • Males and females aged 18 - 55 years Exclusion: • Administration of any investigational drug within the previous 2 months before enrolment (4 months if the previous drug was a new chemical entity)
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To evaluate the efficacy of a selected treatment regimen of ATL 1102 in patients with Relapsing Remitting MS (RRMS) inflammatory lesions using MRI with gadolinium administration compared to placebo.
Loading reviews and guidelines…
History
Started
Oct 2006